Published in Structure on April 01, 2003
Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go. Br J Pharmacol (2007) 2.13
UFSRAT: Ultra-fast Shape Recognition with Atom Types--the discovery of novel bioactive small molecular scaffolds for FKBP12 and 11βHSD1. PLoS One (2015) 1.40
The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins. Nat Protoc (2015) 1.26
Docking screens: right for the right reasons? Curr Top Med Chem (2009) 1.05
Selectivity and potency of cyclin-dependent kinase inhibitors. AAPS J (2006) 1.04
Transferable scoring function based on semiempirical quantum mechanical PM6-DH2 method: CDK2 with 15 structurally diverse inhibitors. J Comput Aided Mol Des (2011) 0.90
Ligand discovery and virtual screening using the program LIDAEUS. Br J Pharmacol (2007) 0.89
Sanjeevini: a freely accessible web-server for target directed lead molecule discovery. BMC Bioinformatics (2012) 0.88
Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity. J Med Chem (2013) 0.86
Analogs of N'-hydroxy-N-(4H,5H-naphtho[1,2-d]thiazol-2-yl)methanimidamide inhibit Mycobacterium tuberculosis methionine aminopeptidases. Bioorg Med Chem (2012) 0.83
Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53-HDM2 Protein-Protein Interaction. Int J Pept Res Ther (2006) 0.81
Crystal structure of human cyclin-dependent kinase-2 complex with MK2 inhibitor TEI-I01800: insight into the selectivity. J Synchrotron Radiat (2013) 0.80
Discovery of a new class of inhibitors for the protein arginine deiminase type 4 (PAD4) by structure-based virtual screening. BMC Bioinformatics (2012) 0.79
Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. J Med Chem (2016) 0.79
Efficient soluble expression of active recombinant human cyclin A2 mediated by E. coli molecular chaperones. Protein Expr Purif (2015) 0.77
Drug targets for cell cycle dysregulators in leukemogenesis: in silico docking studies. PLoS One (2014) 0.75
Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature (2002) 37.66
International network of cancer genome projects. Nature (2010) 20.35
p53 in health and disease. Nat Rev Mol Cell Biol (2007) 11.33
Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol Syst Biol (2007) 8.16
p53 isoforms can regulate p53 transcriptional activity. Genes Dev (2005) 6.76
Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer (2009) 5.12
Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Sci Transl Med (2013) 4.62
Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell (2004) 4.46
Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization. Curr Biol (2004) 3.45
Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell (2008) 3.38
Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol (2003) 3.20
p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev (2009) 2.57
Translating p53 into the clinic. Nat Rev Clin Oncol (2010) 2.55
The role of mutant p53 in human cancer. J Pathol (2010) 2.49
MeCP2 binding to DNA depends upon hydration at methyl-CpG. Mol Cell (2008) 2.48
p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol (2009) 2.46
Loss of function of def selectively up-regulates Delta113p53 expression to arrest expansion growth of digestive organs in zebrafish. Genes Dev (2005) 2.44
Protein recognition of macrocycles: binding of anti-HIV metallocyclams to lysozyme. Proc Natl Acad Sci U S A (2005) 2.31
Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int (2005) 2.29
Predictive adaptive responses to maternal high-fat diet prevent endothelial dysfunction but not hypertension in adult rat offspring. Circulation (2004) 2.28
Gene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquine-resistant rodent malaria parasites. Mol Microbiol (2007) 2.18
The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor. EMBO J (2005) 2.12
Transcription - guarding the genome by sensing DNA damage. Nat Rev Cancer (2004) 2.10
The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J (2007) 2.07
Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res (2005) 2.06
The pluripotency rheostat Nanog functions as a dimer. Biochem J (2008) 1.97
Targeting Mnks for cancer therapy. Oncotarget (2012) 1.96
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov (2007) 1.92
Cell type-specific responses of human cells to inhibition of replication licensing. Oncogene (2002) 1.91
Molecular architecture of the Mos1 paired-end complex: the structural basis of DNA transposition in a eukaryote. Cell (2009) 1.88
Use of a computerized guideline for glucose regulation in the intensive care unit improved both guideline adherence and glucose regulation. J Am Med Inform Assoc (2004) 1.85
In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer (2002) 1.84
Clinical Practice Guidelines and Recommendations on Peritoneal Dialysis Adequacy 2011. Perit Dial Int (2011) 1.76
Hypophosphorylation of Mdm2 augments p53 stability. Mol Cell Biol (2002) 1.68
Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. Chem Biol (2010) 1.66
Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Cell Cycle (2009) 1.64
Computer-aided detection in the United Kingdom National Breast Screening Programme: prospective study. Radiology (2005) 1.63
Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget (2010) 1.62
Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo. J Biol Chem (2004) 1.61
Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design. Proc Natl Acad Sci U S A (2005) 1.57
Mechanism of Mos1 transposition: insights from structural analysis. EMBO J (2006) 1.48
Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol (2006) 1.47
Ubiquitination of HEXIM1 by HDM2. Cell Cycle (2009) 1.46
Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol Sci (2008) 1.46
Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. EMBO J (2009) 1.45
Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin Cancer Res (2008) 1.44
Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53. J Biol Chem (2008) 1.43
A cyclic pentapeptide derived from the second EGF-like domain of Factor VII is an inhibitor of tissue factor dependent coagulation and thrombus formation. Thromb Haemost (2002) 1.43
Extensive DNA mimicry by the ArdA anti-restriction protein and its role in the spread of antibiotic resistance. Nucleic Acids Res (2009) 1.38
Global proteomic assessment of the classical protein-tyrosine phosphatome and "Redoxome". Cell (2011) 1.34
Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem (2010) 1.32
Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. J Mol Biol (2005) 1.31
Atomic structure of Mycobacterium tuberculosis CYP121 to 1.06 A reveals novel features of cytochrome P450. J Biol Chem (2002) 1.31
Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways. Nat Rev Drug Discov (2008) 1.30
p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res (2011) 1.29
Nutlin-3 inhibits the NFkappaB pathway in a p53-dependent manner: implications in lung cancer therapy. Cell Cycle (2007) 1.28
Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. Oncotarget (2011) 1.27
Molecular simulations of protein dynamics: new windows on mechanisms in biology. EMBO Rep (2008) 1.25
Reactivation of p53: from peptides to small molecules. Trends Pharmacol Sci (2010) 1.25
Crystal structure of dihydrofolate reductase from Plasmodium vivax: pyrimethamine displacement linked with mutation-induced resistance. Proc Natl Acad Sci U S A (2005) 1.22
HEXIM1 and the control of transcription elongation: from cancer and inflammation to AIDS and cardiac hypertrophy. Cell Cycle (2007) 1.22
p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. J Clin Invest (2013) 1.21
Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. J Thorac Oncol (2013) 1.17
Small-molecule inhibitors of MDM2 as new anticancer therapeutics. Semin Cancer Biol (2009) 1.17
S-nitrosylation of AtSABP3 antagonizes the expression of plant immunity. J Biol Chem (2008) 1.16
Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2. J Am Chem Soc (2008) 1.16
Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence. Nat Cell Biol (2010) 1.14
Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem (2009) 1.14
Dietary soy isoflavone induced increases in antioxidant and eNOS gene expression lead to improved endothelial function and reduced blood pressure in vivo. FASEB J (2005) 1.14
Stapled peptides with improved potency and specificity that activate p53. ACS Chem Biol (2012) 1.14
A structure-based mutational analysis of cyclophilin 40 identifies key residues in the core tetratricopeptide repeat domain that mediate binding to Hsp90. J Biol Chem (2002) 1.13
Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets? Trends Pharmacol Sci (2004) 1.13
Characterization, crystallization and preliminary X-ray analysis of bifunctional dihydrofolate reductase-thymidylate synthase from Plasmodium falciparum. Acta Crystallogr D Biol Crystallogr (2004) 1.13
Visuomotor priming by pictures of hand postures: perspective matters. Neuropsychologia (2003) 1.12
In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res (2005) 1.11
Progress in the discovery of polo-like kinase inhibitors. Curr Top Med Chem (2005) 1.11
P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2. FEBS Lett (2002) 1.10